Selective internal radiation therapy
Ask the expert
The report presents a summary of reimbursement situation for selective internal radiation therapy in Europe.
The following indications will be considered:
- Primary liver cancer (hepatocellular carcinoma);
- Metastatic liver cancer.
Different types of microspheres for SIRT will be covered in the report, including those use the radionuclide yttrium-90 and based on the radionuclide holmium-166.
The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of treatment of selective internal radiation therapy (SIRT):
- Bio-Rad (Bio-Rex, Aminex)
- BTG (TheraSphere)
- Sirtex (Sir-spheres)
- Terumo (QuiremScout, QuiremSpheres)
Table of content is not available at the moment. Report is still ongoing.
At the beginning of September 2021, the Government of the Russian Federation released the preliminary version of the Program of State Guarantees for the period of 2022-2024. Major changes concerned the High-End Medical Care (HEMC) list I, where two new procedures in the cardiovascular and neurovascular field were added. The HEMC list II was expanded with the procedures in the field of radiotherapy, neurology, and neurosurgery, surgical procedures. The final version is expected at the beginning of 2022.Read more
On August 05, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering April 27, 2021 - July 27, 2021). No new MedTech-related Clinical Commissioning Policies were added to the work program. Nine new policies were published; however, only two concerned MedTech (ECMO and brachytherapy). The status of ongoing policies was updated as well.Read more
On July 30, 2021, the Swiss Federal Statistics Office (UFS) published the 2022 version of the procedure code (CHOP) nomenclature in the German language. The newly introduced codes concern various technology groups, such as cardiovascular, gastrointestinal, neurology, interventional radiology, orthopedics, gynecology, and others.Read more
The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.Read more
On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).Read more